Foghorn Therapeutics Announces Director Departure, New Appointments
Ticker: FHTX · Form: 8-K · Filed: Dec 30, 2024 · CIK: 1822462
| Field | Detail |
|---|---|
| Company | Foghorn Therapeutics Inc. (FHTX) |
| Form Type | 8-K |
| Filed Date | Dec 30, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, board-composition, executive-compensation
Related Tickers: FHTX
TL;DR
Foghorn Therapeutics (FHTX) director Astrachan out, new board members and officers in. Details light.
AI Summary
Foghorn Therapeutics Inc. announced on December 29, 2024, the departure of Director Jeffrey J. Astrachan. The company also elected new directors and appointed new officers, along with changes to compensatory arrangements for certain officers. The filing does not specify the reasons for Mr. Astrachan's departure or the details of the new appointments and compensation.
Why It Matters
Changes in board composition and officer appointments can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Director departures and executive changes can introduce uncertainty regarding company direction and stability.
Key Numbers
- 001-39634 — SEC File Number (Identifies Foghorn Therapeutics Inc. in SEC filings.)
- 20241229 — Report Date (The date of the earliest event reported in this 8-K filing.)
Key Players & Entities
- Foghorn Therapeutics Inc. (company) — Registrant
- Jeffrey J. Astrachan (person) — Departing Director
- December 29, 2024 (date) — Date of earliest event reported
- 001-39634 (company) — SEC File Number
- 500 Technology Square, Ste 700 Cambridge, MA (location) — Business Address
FAQ
Who is the departing director and when did their departure become effective?
Director Jeffrey J. Astrachan departed, with the earliest event reported as of December 29, 2024.
What are the key items reported in this 8-K filing?
The filing reports the departure of a director, election of directors, appointment of certain officers, and compensatory arrangements of certain officers.
What is Foghorn Therapeutics Inc.'s SEC file number?
Foghorn Therapeutics Inc.'s SEC file number is 001-39634.
When is Foghorn Therapeutics Inc.'s fiscal year end?
Foghorn Therapeutics Inc.'s fiscal year ends on December 31.
What is the business address of Foghorn Therapeutics Inc.?
The business address is 500 Technology Square, Suite 700, Cambridge, MA 02139.
Filing Stats: 468 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-12-30 07:54:12
Key Financial Figures
- $0.0001 — ge on which registered Common Stock, $0.0001 par value per share FHTX The Nasdaq Glo
Filing Documents
- fhtx-20241229.htm (8-K) — 29KB
- 0001628280-24-052539.txt ( ) — 153KB
- fhtx-20241229.xsd (EX-101.SCH) — 2KB
- fhtx-20241229_lab.xml (EX-101.LAB) — 22KB
- fhtx-20241229_pre.xml (EX-101.PRE) — 13KB
- fhtx-20241229_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. FOGHORN THERAPEUTICS INC. By: /s/ Kristian Humer Kristian Humer Chief Financial Officer Date: December 30, 2024